Literature DB >> 7607536

Selection of recombinant vaccinia viruses on the basis of plaque formation.

R Blasco1, B Moss.   

Abstract

We developed a procedure for isolation of recombinant vaccinia viruses (re-VV) based solely on plaque formation, without a requirement for specific cell lines, selective medium or special staining. The system consists of two components: (i) a mutant non-plaque-forming VV and (ii) a plasmid vector that, through homologous recombination, can simultaneously introduce a foreign gene and repair mutation in the VV genome. The mutant VV contains a deletion of the vp37 gene, encoding a 37-kDa protein component of the viral outer envelope that is required for efficient viral spread on cell monolayers. The plasmid vector contains a functional vp37, a strong synthetic VV early/late promoter, unique restriction sites for gene insertion, and flanking segments of VV DNA for homologous recombination. Following infection and transfection of cells with the mutant VV and plasmid vector, respectively, re-VV are identified and isolated by their ability to form plaques. To evaluate the system, a re-VV that expresses the gene encoding influenza virus hemagglutinin (HA) was isolated simply by picking visible plaques.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7607536     DOI: 10.1016/0378-1119(95)00149-z

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  99 in total

1.  Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1.

Authors:  N W Blake; A Moghaddam; P Rao; A Kaur; R Glickman; Y G Cho; A Marchini; T Haigh; R P Johnson; A B Rickinson; F Wang
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  MHC I-dependent antigen presentation is inhibited by poliovirus protein 3A.

Authors:  S B Deitz; D A Dodd; S Cooper; P Parham; K Kirkegaard
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

3.  Recombinant vaccinia viruses. Design, generation, and isolation.

Authors:  C C Broder; P L Earl
Journal:  Mol Biotechnol       Date:  1999-12-15       Impact factor: 2.695

4.  Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion.

Authors:  L González-Reyes; M B Ruiz-Argüello; B García-Barreno; L Calder; J A López; J P Albar; J J Skehel; D C Wiley; J A Melero
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-07       Impact factor: 11.205

5.  Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways.

Authors:  William A Langley; Konrad C Bradley; Zhu-Nan Li; Mary Ellen Smith; Matthias J Schnell; David A Steinhauer
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

6.  Characterization of hepatitis E virus recombinant ORF2 proteins expressed by vaccinia viruses.

Authors:  Nereida Jiménez de Oya; Estela Escribano-Romero; Ana-Belén Blázquez; María Lorenzo; Miguel A Martín-Acebes; Rafael Blasco; Juan-Carlos Saiz
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

7.  Vaccinia virus entry into cells via a low-pH-dependent endosomal pathway.

Authors:  Alan C Townsley; Andrea S Weisberg; Timothy R Wagenaar; Bernard Moss
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

8.  Association of vaccinia virus fusion regulatory proteins with the multicomponent entry/fusion complex.

Authors:  Timothy R Wagenaar; Bernard Moss
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

9.  Characterization of ectromelia virus deficient in EVM036, the homolog of vaccinia virus F13L, and its application for rapid generation of recombinant viruses.

Authors:  Felicia Roscoe; Ren-Huan Xu; Luis J Sigal
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

Review 10.  Reflections on the early development of poxvirus vectors.

Authors:  Bernard Moss
Journal:  Vaccine       Date:  2013-04-10       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.